Advanced Breast Cancer

Standard of care testing for BRCA1/2, ERBB2 (HER2), MSI, ESR1, NTRK1/2/3, and PIK3CA.

Download Study
Advanced breast cancer pre-treatment imaging.

Pre-treatment imaging

Advanced breast cancer post-treatment imaging.

Post-treatment imaging
*Representative patient images

Patient Case

Clinical presentation
  • 56-year-old female previously treated for early-stage breast cancer
  • Patient was ER+/HER2-
  • Upon metastatic progression, she was put on CDK4/6 inhibitor (IBRANCE®)
  • After 10 months of therapy, the patient showed signs of clinical progression via CT scan
  • Patient had no prior genomic testing
  • Oncologist ordered Guardant360® to receive guideline-recommended results within 7 days-
  • The patient was found to have an activating PIK3CA mutation
  • Oncologist started the patient on a PI3K inhibitor with a partial response that lasted more than 9 months

You might also be interested in

Advanced CRC imaging.
Advanced CRC

Standard of care in CRC requires testing for BRAF, ERBB2 (HER2), KRAS, MSI, NRAS, and NTRK.

Advanced lung cancer imaging.
Advanced Lung Cancer

Standard of care in NSCLC requires testing for ALK, BRAF, EGFR, ERBB2, KRAS, MET, NTRK, RET, ROS1.